Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $44.00 Average PT from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given an average rating of “Moderate Buy” by the five analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $44.00.

A number of equities research analysts recently commented on INO shares. HC Wainwright reissued a “neutral” rating and issued a $15.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, July 15th. Oppenheimer lowered their price target on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th. Stephens began coverage on Inovio Pharmaceuticals in a research report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on Inovio Pharmaceuticals from $11.00 to $8.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th.

Inovio Pharmaceuticals Trading Down 3.4 %

INO stock opened at $6.28 on Tuesday. The company has a market cap of $162.72 million, a price-to-earnings ratio of -1.71 and a beta of 0.83. The firm has a 50 day moving average of $8.85 and a 200-day moving average of $9.91. Inovio Pharmaceuticals has a 12-month low of $3.89 and a 12-month high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.09). Inovio Pharmaceuticals had a negative return on equity of 99.51% and a negative net margin of 16,238.91%. The firm had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same quarter in the previous year, the firm posted ($1.56) earnings per share. Sell-side analysts forecast that Inovio Pharmaceuticals will post -4.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in INO. The Manufacturers Life Insurance Company purchased a new position in Inovio Pharmaceuticals during the second quarter worth approximately $82,000. Signature Estate & Investment Advisors LLC purchased a new position in shares of Inovio Pharmaceuticals in the 2nd quarter worth $88,000. Cornercap Investment Counsel Inc. purchased a new position in shares of Inovio Pharmaceuticals in the 2nd quarter worth $184,000. American Century Companies Inc. grew its position in Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after acquiring an additional 12,100 shares during the period. Finally, Rhumbline Advisers grew its position in Inovio Pharmaceuticals by 5,943.0% during the second quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 37,857 shares during the period. Hedge funds and other institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.